Tuesday, February 17, 2009 8:00 am - 7:00 pm (Eastern Time)
Preliminary Agenda
Please visit this page for presentation schedule updates. If you are interested in more information or conference sponsorship, please contact us.
7:00 - 8:00 |
Registration & Continental Breakfast Welcome & Introductions to the Stem Cell Summit |
8:00 - 8:15 | Overall Welcome &Introduction to the 4th Annual Stem Cell Summit - The Outlook for Commercialization in Stem Cells
2009-2019 |
 |
Robin R. Young, CFA |
President and Publisher RRY Publications & PearlDiver Data, Inc. |
8:15 - 8:35 |
Cell Therapy: MSCs as Regulated Drugstores |
 |
Arnold Caplan, PhD |
Professor of Biology and General Medicine Sciences (Oncology) Case Western Reserve University |
8:35 - 4:15 |
Embryonic Stem Cells |
8:35 - 8:45 |
Novocell, Inc. |
 |
Mitch
Fisher, Senior Vice President |
Novocell, Inc. is a stem cell engineering company dedicated to creating, delivering and commercializing cell and drug therapies to treat diabetes and other chronic diseases. |
8:47 - 8:57 |
Geron Corp. |
 |
Jane S. Lebkowski, PhD, Sr. Vice President |
Geron Corporation develops and commercializes cell-based therapies derived from its human embryonic stem cell platform for applications in various diseases. |
8:59 - 9:09 |
California Stem Cell, Inc. |
 |
Hans S. Keirstead, PhD, Chairman, Scientific Advisory Board |
California Stem Cell is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. |
9:11 - 9:21 |
Stemina, Inc. |
 |
Gabriela Cezar, DVM, PhD, Chief Scientific Officer |
Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics |
9:23 - 9:33 |
Histogen, Inc. |
 |
Gail K. Naughton, Ph.D, CEO |
Histogen, Inc. is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment. |
9:35 - 9:45 |
Aruna Biomedical, Inc. |
 |
Steven Stice, PhD, Chairman and Chief Scientific Officer |
Aruna Biomedical is a pioneer and leader in providing innovative products and services derived from human stem cells. |
|
9:47 - 9:57 |
Aldagen, Inc. |
 |
Ed Field, President & COO |
Aldagen is a regenerative medicine company developing and commercializing products to treat vascular and degenerative diseases. |
9:59
- 10:09 |
Genzyme |
 |
Stephen
Potter Senior
Vice President
, Corporate Development |
Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. |
10:11
- 10:23 |
Osiris therapeutics |
 |
C. Randal Mills, PhD, President, CEO, & Director |
Chondrogen™ is currently being evaluated in a clinical trial for regeneration of the meniscus in the knee and prevention of osteoarthritis. |
10:25
- 10:35 |
MaxCyte, Inc. |
 |
Madhusudan
Peshwa, Ph.D, Vice President, Research & Development |
Maxcyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. |
10:37
- 10:47 |
AllCells, LLC |
 |
Jay Tong,
CEO |
AllCells’ products include a wide variety of unprocessed and purified normal human blood and bone marrow cells. |
10:49
- 10:59 |
Moraga Biotechnology Corporation |
 |
John F. Wong, PhD, Chairman & CEO |
Moraga Biotechnology Corporation is an adult stem cell-based company headquartered in Los Angeles, California. |
11:01
- 11:11 |
Arteriocyte, Inc. |
 |
Donald J. Brown, CEO |
Arteriocyte’s focus is stem cell-based therapies to treat ischemia in patients with coronary artery disease, peripheral vascular disease, stroke, and renal ischemia. |
11:13
- 11:23 |
Aastrom Biosciences, Inc. |
 |
George W. Dunbar, CEO, President & Director |
Aastrom Biosciences, Inc. is developing autologous cell products based on its proprietary Tissue Repair Cell (TRC) technology. |
11:25
- 11:35 |
Gamida Cell Ltd. |
 |
Yael Margolin, PhD, CEO |
Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. |
11:37
- 11:47 |
Stematix |
 |
David
C. Boner Chairman & CEO |
Stematix is a regenerative medicine technology and solutions provider positioned to accelerate safe and effective global use of stem cell therapies. |
11:49
- 11:59 |
Garnet
BioTherapeutics,
Inc. |
 |
Gerri
Henwood, CEO |
Garnet BioTherapeutics is developing the next generation of biomedicines by harnessing the therapeutic potential of the human cell. |
|
1:45 - 1:55 |
NuVasive |
 |
Tyler Lipschultz, VP, Biologics |
NuVasive’s mission is to provide safe and reproducible procedural solutions with platform technology for the treatment of lumbar and cervical degenerative conditions. |
1:57 - 2:07 |
TiGenix NV |
 |
Gil Beyen, Managing Director & CEO |
TiGenix is a venture-backed, private biotech company that was created as a spin-off from the universities of Leuven and Gent in Belgium. |
2:09- 2:19 |
Cellerix Living Medicines |
 |
Edwardo Bravo, MBA, CEO |
Cellerix is leading the development of a new generation of treatments using expanded adult stem cells from adipose tissue (eASCs). |
2:21- 2:31 |
StemCyte, Inc. |
 |
Kenneth J. Giacin, MBA, MS Chairman & CEO |
StemCyte, Inc. is a leading, global umbilical cord blood ("UCB") stem cell transplantation and therapeutic products company. StemCyte's products are currently being used to treat two to three patients per week worldwide who suffer from a variety of blood cancers and immune and genetic disorders. |
2:33- 2:43 |
Athersys |
 |
William (B.J.) Lehmann, J.D.
President & CEO |
Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support. |
Tools & Instruments |
2:45 - 2:55 |
Cytori Therapeutics |
 |
Kai
Pinkernell MD, Sr. Director of Regenerative Cell Technology |
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue. |
2:57
- 3:07 |
Cognate BioServices, Inc. |
 |
Alan K. Smith, PhD, |
Cognate BioServices, Inc. provides full support to companies and institutions engaged in the development of cell-based products and therapies. |
3:09
- 3:19 |
Harvest Technologies Corp. |
 |
Gary D. Tureski, Co-Founder & President |
Improving patient outcomes by enhancing the body's normal healing process using adult stem cells and growth factors. |
3:21
- 3:31 |
Vet-Stem, Inc. |
 |
Robert J. Harman, DVM, MPVM CEO & Founder |
Vet-Stem’s regenerative medicine uses a concentrated form of autologous, adipose-derived adult stem cells to treat traumatic and degenerative diseases within the veterinary market. |
3:33
- 3:43 |
BioE Corp. |
 |
Michael Haider, President & CEO |
BioE provides innovative Cell Biologics technologies for the biomedical industry. |
3:45
- 3:55 |
Progenitor Cell Therapy, Inc. |
 |
Robert A. Preti, PhD, President & Chief Scientific Officer |
Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies. |
| 3:57 - 4:07 | Histogenics, Inc. |
 |
F. Ken Andrews President & CEO |
Histogenics develops and manufactures products that improve the body's ability to regenerate healthy cartilage, improve joint function and prevent degenerative disease. |
4:09
- 4:19 |
Tissue Genesis, Inc. |
 |
Stuart Williams, PhD, Chief Science Officer |
Tissue Genesis, Inc. is an emerging highgrowth company in the field of regenerative medicine, using a patient’s own therapeutic cells to coat implants, repair damaged tissue, heal disease, and address other medical concerns. |
4:21
- 4:31 |
Incel Corp. LLC |
 |
Mary Pat Moyer, PhD, Founder, President, CEO & CSO |
INCELL manufactures products for cell culture and research applications. |
4:33 - 4:43 |
SpineSmith Partners LP |
 |
Richard Suzuki, PhD, Director of Research & Development |
SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. Their technology focuses on the stabilization and treatment of spinal and orthopedic disorders. |
4:45 - 5:00 |
|
|||
|
Reception and Networking |
|||
